8
Sep
2020
Becoming a Biotech VC: Otello Stampacchia on The Long Run
Today’s guest on The Long Run is Otello Stampacchia. He’s the founder and managing director of Omega Funds. Otello started Omega in 2004, and it’s now on Fund VI. Based in Boston, Omega has $1 billion under management, and invests in a wide variety of biotech companies – early stage, later stage, American, European, oncology, immunology, rare disease. There’s a... Read More
11
Aug
2020
From Rio to Rome: Rosana Kapeller on The Long Run
Today’s guest on The Long Run is Rosana Kapeller. She’s the president and CEO of Cambridge, Mass.-based ROME Therapeutics. ROME aims to discover and develop drugs based on emerging science in what is sometimes called the “repeatome.” These are long repeat stretches of DNA that scientists until recently knew very little about, and still have a lot to learn about... Read More
21
Jul
2020
The Road Less Traveled in Biotech: Abe Ceesay on The Long Run
Today’s guest on The Long Run is Abe Ceesay. He’s the CEO of Cambridge, Mass.-based Tiburio Therapeutics. The company is developing a couple of drug candidates for rare neuroendocrine tumors. It raised $31 million in a Series A financing in January 2019 from NEA, Lundbeckford Ventures, Longitude Capital, and Alexandria Real Estate Equities. Abe is in his early 40s, and... Read More
6
Jul
2020
Writing in the Language of DNA: Kevin Ness on The Long Run
Today’s guest on The Long Run is Kevin Ness. He’s the CEO of Boulder, CO-based Inscripta. This is a startup that calls itself the “digital genome engineering company.” The aspiration, which Inscripta described in a statement last December, was to create: The world’s first fully automated benchtop instrument for genome-scale engineering. Consisting of an instrument, consumables, software, and assays, it... Read More
10
Jun
2020
Fighting COVID-19 & Racism: Andy Plump on The Long Run
Today’s guest on The Long Run is Andrew Plump. Andy is the president of research and development, and a member of the board of directors, at Takeda Pharmaceutical. Takeda doesn’t get a lot of attention in the US, but it’s one of the world’s biggest pharmaceutical companies by revenue, ranking a little behind AbbVie and a little ahead of Bristol-Myers... Read More
26
May
2020
Finding a Path in Biotech Venture Capital: Nina Kjellson on The Long Run
Today’s guest on The Long Run is Nina Kjellson. Nina is a general partner with Canaan Partners on the West Coast. Her investing style leans toward high science, which you can see in portfolio companies like PACT Pharma, a company developing neoantigen targeted T cell therapies for cancer, Tizona Therapeutics, a targeted antibody developer for cancer, and Vineti, a software... Read More
13
May
2020
Coronavirus Vaccine Strategy: Larry Corey on The Long Run
Today’s guest on The Long Run is Larry Corey. Larry is one of the nation’s best-known virologists and vaccine developers. Much of his research over the years has been on HIV, herpes simplex viruses, and viruses associated with cancer. He’s the founding director and principal investigator of the HIV Vaccine Trials Network – a collaborative group to study vaccine candidates... Read More
30
Apr
2020
Real-Time Tracking of Viral Outbreaks: Emma Hodcroft on The Long Run
Today’s guest on The Long Run is Emma Hodcroft. Emma is a molecular epidemiologist at the University of Basel, and the co-developer of Nextstrain. NextStrain is the open-source toolkit built for real-time tracking of viral outbreaks. In the early days, teams led by Trevor Bedford at Fred Hutch and Richard Neher in Basel used it to track viral evolution of... Read More
17
Apr
2020
Hunting for Antibodies Against COVID19: George Scangos on The Long Run
Today’s guest on The Long Run is George Scangos. George is the CEO of San Francisco-based VIR Biotechnology. VIR has been all over the news the past couple months. It’s at the forefront of companies racing to discover and develop broadly neutralizing antibodies against the SARS-CoV-2 virus that’s sparked a global pandemic. VIR was founded in early 2017 by some... Read More
4
Apr
2020
Diagnostic Dysfunction for COVID19: Mike Pellini on The Long Run
Today’s guest on The Long Run is Mike Pellini. Mike is a managing partner with Section32, a venture firm that invests in biotech startups. Mike is an expert in diagnostics. He was previously the CEO of Foundation Medicine, a company that looks at a wide range of gene mutations in tumor samples to can act as molecular drivers of cancer.... Read More
23
Mar
2020
New Drugs at Low Prices: Alexis Borisy and Melanie Nallicheri of EQRx on The Long Run
Today’s guests on The Long Run are Alexis Borisy and Melanie Nallicheri. Alexis is the chairman and CEO of EQRx, and Melanie is the president and chief operating officer. EQRx is a startup in Cambridge, Massachusetts. It aspires to develop new medicines for serious diseases like cancer. That’s nothing unusual. What is unusual is that EQRx is seeking to create... Read More
9
Mar
2020
Living Life Fully with Stage 4 Lung Cancer: Isabella de le Houssaye on The Long Run
Today’s guest on The Long Run is Isabella de la Houssaye. Isabella is a former attorney on Wall Street, a mother of five kids, and a terrific endurance athlete. She’s run marathons around the country, ultramarathons, and even completed an Ironman triathlon. She’s also a Stage 4 lung cancer patient. She owes her life, and her vitality, to some extraordinary... Read More
24
Feb
2020
Facing Up to a Political Crisis: BIO Chairman Jeremy Levin on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Feb
2020
The Cell Therapy Puzzle: Jane Grogan on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Jan
2020
Scientists at the Movies: Relay Therapeutics CEO Sanjiv Patel on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jan
2020
A New Cholesterol-Lowering Drug at a Low Price: Tim Mayleben on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Dec
2019
Designer Proteins as Better Therapies: David Baker on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Dec
2019
Sticking With Epigenetics During Lean Times: Jigar Raythatha on The Long Run
Today’s guest on The Long Run is Jigar Raythatha. Jigar is the CEO of Cambridge, Mass.-based Constellation Pharmaceuticals. This company is built to develop drugs against epigenetic targets. Simply put, this is a way to turn genes on or off without altering the underlying DNA. The pharmaceutical industry fancied this idea about a decade ago, as a way to shut... Read More
26
Nov
2019
Tamping Down Inflammation & Synaptic Dysfunction in Alzheimer’s: John Alam on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Nov
2019
Scientist, Entrepreneur, Rock Collector: Tim Springer on The Long Run
Today’s guest on The Long Run is Tim Springer. Tim wears many hats. First and foremost, he’s a scientist. An immunologist to be specific, at Harvard Medical School. He’s best known for his discovery of integrins, a class of transmembrane receptors. Now in his early 70s, Tim recently won the Gairdner Award, sometimes called the Canadian Nobel. The prize committee... Read More